| Adverse events (grade ≥ 3) | Availability | Effect | Heterogeneity | Model | ||||
| Trials (N) | HD (events/total) | SD (events/total) | OR (95% CI) | P value | I2 | P value |
| |
| Treatment-related deaths | 7 | 28/555 | 27/569 | 1.06 (0.62 - 1.83) | 0.83 | 0% | 0.94 | FE |
| Esophagitis | 4 | 55/264 | 51/271 | 1.12 (0.72 - 1.77) | 0.61 | 0% | 0.90 | FE |
| Other esophageal toxicities* | 6 | 26/502 | 22/510 | 1.20 (0.67 - 2.16) | 0.53 | 0% | 0.58 | FE |
| Neutropenia/Leukopenia | 4 | 107/264 | 112/271 | 0.94 (0.65 - 1.35) | 0.74 | 1% | 0.32 | FE |
| Respiratory toxicities** | 5 | 19/394 | 9/401 | 2.11 (0.97 - 4.58) | 0.06 | 0% | 0.46 | FE |